Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO versus SEVELAMER HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO versus SEVELAMER HYDROCHLORIDE.
PHOSLO vs SEVELAMER HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds phosphate in the gastrointestinal tract, forming insoluble calcium phosphate that is excreted in feces, thereby reducing serum phosphate levels.
Sevelamer hydrochloride is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and thereby reducing serum phosphate levels.
667 mg (two 667-mg tablets or one 667-mg capsule) orally three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL; maximum 4000 mg/day.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 800 mg per meal at 2-week intervals based on serum phosphorus levels. Maintenance: typically 2.4-4.8 g/day divided with meals.
None Documented
None Documented
Not applicable; minimal systemic absorption, local gastrointestinal action
Not applicable; sevelamer is not absorbed. The polymer acts locally in the gastrointestinal tract and does not have a measurable plasma half-life.
Primarily fecal as unabsorbed drug; minimal renal elimination (<0.5%)
Sevelamer hydrochloride is not absorbed systemically; it is eliminated entirely in the feces as the unchanged polymer. No renal or biliary elimination occurs.
Category C
Category A/B
Phosphate Binder
Phosphate Binder